Global Oral Ursodeoxycholic Acid Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Oral Ursodeoxycholic Acid market size was valued at US$ 2050 million in 2024 and is forecast to a readjusted size of USD 4231 million by 2031 with a CAGR of 11.0% during review period.

Ursodeoxycholic acid, whose chemical name is 3a,7β-dihydroxy-5β-cholestane-24-acid, is an organic compound with an odorless, bitter taste. It is used in medicine to increase the secretion of bile acid, change the composition of bile, reduce cholesterol and cholesterol lipid in bile, and help the cholesterol in gallstones to gradually dissolve.

The Ursodeoxycholic Acid (UDCA) drug market is driven by the increasing prevalence of liver and gallbladder disorders and the growing adoption of UDCA as an effective treatment option. UDCA is a naturally occurring bile acid that helps dissolve cholesterol-rich gallstones and aids in the treatment of certain liver diseases, such as primary biliary cholangitis (PBC) and nonalcoholic fatty liver disease (NAFLD). The rise in liver-related conditions and the need for improved therapeutic options contribute to market growth as UDCA offers a well-tolerated and disease-modifying treatment for these disorders. Moreover, advancements in drug formulations and the development of combination therapies have enhanced the efficacy of UDCA treatment. However, the market also faces challenges, including the cost of UDCA drugs and the need for further research to optimize dosing and treatment protocols. Additionally, addressing regulatory requirements and ensuring accessibility to patients can pose obstacles for broader adoption. To succeed, companies must focus on research and development to offer innovative and affordable UDCA drugs, collaborate with hepatologists to optimize treatment approaches, and address the challenges to meet the increasing demand for effective and well-tolerated therapeutic options for liver and gallbladder disorders.

This report is a detailed and comprehensive analysis for global Oral Ursodeoxycholic Acid market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Oral Ursodeoxycholic Acid market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Oral Ursodeoxycholic Acid market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Oral Ursodeoxycholic Acid market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Oral Ursodeoxycholic Acid market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Oral Ursodeoxycholic Acid

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Oral Ursodeoxycholic Acid market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini, Impax, Shanghai Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Oral Ursodeoxycholic Acid market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Tablet

Capsule

Market segment by Application

Gallstones

Liver Disease

Stomach Trouble

Other

Major players covered

Dr. Falk Pharma

Daewoong Pharmaceutical

Teva

Epic Pharma

Mitsubishi Tanabe Pharma

Lannett

Mylan

Bruschettini

Impax

Shanghai Pharma

Grindeks

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Oral Ursodeoxycholic Acid product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Oral Ursodeoxycholic Acid, with price, sales quantity, revenue, and global market share of Oral Ursodeoxycholic Acid from 2020 to 2025.

Chapter 3, the Oral Ursodeoxycholic Acid competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Oral Ursodeoxycholic Acid breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Oral Ursodeoxycholic Acid market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Oral Ursodeoxycholic Acid.

Chapter 14 and 15, to describe Oral Ursodeoxycholic Acid sales channel, distributors, customers, research findings and conclusion.